New and experimental therapies for HCV

@article{Pereira2009NewAE,
  title={New and experimental therapies for HCV},
  author={Arema A. Pereira and I M for the New Paradigm of HCV Therapy Meeting Part Jacobson},
  journal={Nature Reviews Gastroenterology &Hepatology},
  year={2009},
  volume={6},
  pages={403-411}
}
Despite improvements to treatments for HCV infection, almost half of patients cannot be cured with standard combination therapy (pegylated interferon α and ribavirin). The HCV life cycle offers a number of potential targets for molecular therapy, and several specifically targeted antiviral therapies for HCV (STAT-Cs) are in preclinical and clinical stages of development. Evidence to date suggests that monotherapy with any antiviral drug is unlikely to eradicate HCV infection. Combination… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 26 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 95 references

Antiviral activity of filibuvir in combination with pegylated interferon alfa ‐ 2 a and ribavirin for 28 days in treatment naïve patients chronically infected with HCv genotype 1

i. Jacobson
Presented at the 44 th Annual Meeting of the european Association for the study of the Liver • 2009

Gi ‐ 5005 immunotherapy plus peg ‐ iFN / ribavirin versus peg ‐ iFN / ribavirin in genotype 1 chronic HCv subjects ; preliminary phase 2 evr analyses

B. e. Korba
Presented at the 44 th Annual Meeting of the european Association for the study of the Liver • 2009

Preclinical pharmacokinetic and ADMe characterization of vCH ‐ 222 , a novel non ‐ nucleoside HCv Ns 5 B polymerase inhibitor

N. Chauret
Presented at the 44 th Annual Meeting of the european Association for the study of the Liver • 2009

Preclinical pharmacokinetic and ADMe characterization of vCH‐222, a novel non‐nucleoside HCv Ns5B polymerase inhibitor. Presented at the 44th Annual Meeting of the european Association for the study

N Chauret
Liver • 2009

efficacy and safety of albinterferon alfa‐2B in combination with ribavirin in treatment‐naive, chronic hepatitis C genotype 1 (CHC G1) patients [Abstract 1041

Zeuzem
J. Hepatol • 2009

efficacy and safety results of albinterferon alfa‐2B in combination with ribavirin in interferon‐alfa treatment naive patients with genotype 2 or 3 chronic hepatitis C [abstract 1042

D Nelson
J. Hepatol • 2009

Similar Papers

Loading similar papers…